47 completed, 17 unknown, 15 terminated, 11 recruiting. 111 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 111 | Completed 47, Unknown 17, Terminated 15, Recruiting 11, Active not recruiting 8, Withdrawn 8, Not yet recruiting 5 |
Follow Lymphoma, Large B-Cell, Diffuse: new trials by email Literature Review of Lymphoma, Large B-Cell, Diffuse trials Research Report on Lymphoma, Large B-Cell, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T) - Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL) | Not applicable | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2026-09-01 | 2026-02-17 |
| R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma Penpulimab, Rituximab, Methotrexate - Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Not yet recruiting | WEI XU | 58 | 2026-08-01 | 2026-08-14 |
| Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment Geriatric-guided supportive care, Conventional supportive care - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | Not applicable | Not yet recruiting | Fondazione Italiana Linfomi - ETS | 170 | 2026-05-01 | 2026-04-15 |
| Proton Therapy for Mediastinal Lymphoma (PROMLY) Proton therapy - Mediastinal Lymphoma, Hodgkin Disease Lymphoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 139 | 2026-05-01 | 2026-09-14 |
| Hyperfractionated Dual Equivalent Fractionated Radiation Therapy Bridging Radiation Therapy - Diffuse Large B-Cell Lymphoma | Not applicable | Recruiting | Yale University | 10 | 2025-10-30 | 2026-06-22 |
| ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment - Lymphoma, Lymphoma, B-Cell | Not applicable | Recruiting | Hua-Jay J Cherng, MD | 40 | 2024-12-11 | 2026-01-23 |
| Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL Induction therapy-Pro regimen, Consolidation therapy-Pro-pola regimen - Diffuse Large B-Cell Lymphoma | Not applicable | Recruiting | The First Affiliated Hospital of Soochow University | 43 | 2024-11-01 | 2025-07-18 |
| Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma blood sampling - Follicular Lymphoma, Diffuse Large B-Cell Lymphoma | Not applicable | Active not recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 40 | 2024-09-30 | 2026-10-05 |
| Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR） - Diffuse Large B-cell Lymphoma (DLBCL) | Not applicable | Unknown | Zhejiang Cancer Hospital | 30 | 2024-09-01 | 2025-02-18 |
| A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece A manualised post-traumatic growth intervention for people with hematological cancers - Blood Cancers, Leukemia | Not applicable | Active not recruiting | University of West Attica | 80 | 2024-06-06 | 2026-09-10 |
| Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma? Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients, Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers - Diffuse Large B Cell Lymphoma | Not applicable | Recruiting | University Hospital, Montpellier | 85 | 2024-05-22 | 2026-06-22 |
| Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors Lifestyles Implemented-Survivorship Care Plan (LS-SCP) - Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | Not applicable | Recruiting | Fondazione Italiana Linfomi - ETS | 552 | 2024-02-26 | 2026-09-11 |
| Plasma cfDNA Testing Guiding the Treatment Decisions of DLBCL cfDNA - Lymphoma, Large B-Cell, Diffuse | Not applicable | Not yet recruiting | Second Affiliated Hospital of Soochow University | 30 | 2024-02-25 | 2024-03-04 |
| Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) Adaptive Bridging Radiation Therapy (ABRT) - Lymphoma, B-Cell, Relapsed Cancer | Not applicable | Completed | Massachusetts General Hospital | 10 | 2024-01-14 | 2026-10-15 |
| Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy Measure of the circulating tumor DNA - Diffuse Large B Cell Lymphoma | Not applicable | Completed | Centre Henri Becquerel | 24 | 2023-12-21 | 2026-01-02 |
| Hypnosis: a Path to Appeasement anxiety questionnaire - Hematologic Cancer | Not applicable | Recruiting | Hospices Civils de Lyon | 50 | 2023-10-30 | 2025-09-11 |
| The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. Mitoxantrone hydrochloride liposome injection, RiTUXimab Injection, Cyclophosphamid - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Hospital of Jilin University | 20 | 2023-09-01 | 2023-08-18 |
| Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers Hematolo-GIST Training, Participants Appointment - Lymphoma, B-Cell, Lymphoma | Not applicable | Recruiting | Memorial Sloan Kettering Cancer Center | 48 | 2023-07-03 | 2026-10-13 |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL Venetoclax, Carmustine, Cytarabine - Diffuse Large B Cell Lymphoma | Not applicable | Unknown | Ruijin Hospital | 52 | 2023-06-01 | 2023-05-18 |
| R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Rituximab, Mitoxantrone hydrochloride liposome, Isophosphamide - Diffuse Large B-cell Lymphoma | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-15 | 2023-03-27 |
Showing 20 of 111. Sign in to see all of them.
Lymphoma, Follicular (58) · Lymphoma, Mantle-Cell (55) · Burkitt Lymphoma (52) · Leukemia, Lymphocytic, Chronic, B-Cell (52) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (51) · Lymphoma, Non-Hodgkin (49) · Lymphoma, B-Cell, Marginal Zone (48) · Lymphoma, Large-Cell, Immunoblastic (47) · Hodgkin Disease (45) · Lymphoma (44) · Multiple Myeloma (42) · Lymphoma, T-Cell, Cutaneous (41) · Mycosis Fungoides (38) · Sezary Syndrome (38)
Hemic and Lymphatic Diseases (111) · Immune System Diseases (111) · Immunoproliferative Disorders (111) · Lymphatic Diseases (111) · Neoplasms by Histologic Type (111) · Lymphoma, B-Cell (108) · Lymphoproliferative Disorders (107) · Neoplasms (100) · Lymphoma (67) · Lymphoma, Non-Hodgkin (62) · Pathological Conditions, Signs and Symptoms (59) · Hematologic Diseases (58) · Pathologic Processes (57) · Disease Attributes (56) · Leukemia, Lymphoid (56)
Cyclophosphamide (17) · Rituximab (13) · Peripheral Blood Stem Cell Transplantation (12) · fludarabine phosphate (12) · Cyclosporine (11) · Filgrastim (11) · Mycophenolic Acid (8) · Whole-Body Irradiation (8) · Antilymphocyte Serum (7) · Busulfan (7) · Radiotherapy (7) · Etoposide (6) · Melphalan (6) · Methotrexate (6) · Prednisone (6)
Fred Hutchinson Cancer Center (8) · Roswell Park Cancer Institute (5) · City of Hope Medical Center (4) · Wake Forest University Health Sciences (4) · Case Comprehensive Cancer Center (3) · Centre Henri Becquerel (3) · Duke University (3) · Masonic Cancer Center, University of Minnesota (3) · Memorial Sloan Kettering Cancer Center (3) · Ohio State University Comprehensive Cancer Center (3) · The First Affiliated Hospital with Nanjing Medical University (3) · University of California, San Francisco (3) · Barbara Ann Karmanos Cancer Institute (2) · Eastern Cooperative Oncology Group (2) · Fondazione Italiana Linfomi - ETS (2)
United States (56) · China (14) · France (12) · Italy (7) · South Korea (4) · Germany (3) · Canada (2) · Switzerland (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · Denmark (1) · Greece (1) · Israel (1) · Japan (1)
Ann Woolfrey (2) · Charles A. Linker, MD (2) · Christopher Kelsey, MD (2) · David Maloney (2) · Michael J. Fisch, MD, MPH, FACP (2) · Paul Martin (2) · Philip L. McCarthy, MD (2) · Philip McCarthy (2) · Wei Xu, PhD& MD (2) · Xuejuan Wang, MD (2) · Andrea Kuhnl (1) · Anna Pawlowska, MD (1) · Aprille Seidel, PhD (1) · Barbara A. Murphy, MD (1) · Barrie R. Cassileth, PhD (1)
PMID 32499241, PMID 12525530, PMID 15466923, PMID 16174856, PMID 18698002, PMID 18794865, PMID 21715313, PMID 21719601, PMID 23358983, PMID 26071053, PMID 26150440, PMID 26451310, PMID 28302137, PMID 28817727, PMID 29599530, PMID 32196557, PMID 32223740, PMID 35530320, PMID 37114393, PMID 37964424, PMID 39747123, PMID 40178467, PMID 42426809, PMID 9849691
P30CA015704 (4), P30CA033572 (4), P30CA043703 (3), P30CA022453 (2), 2017 (1), P01CA018029 (1), P30CA006973 (1), P30CA015083 (1), P30CA016056 (1), P30CA016672 (1), P30CA072720 (1), P50CA097274 (1), R01AI058148 (1), R01CA107446 (1), R03CA286676 (1)